Phase 1/2 Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT7480 in Patients With Nectin-4 Associated Advanced Malignancies
Contact:
NCT Number:
Protocol:
AAAU0713
Study Status:
Active/Enrolling
Population:
Adult
Phase:
I/II
The purpose of this study is to evaluate whether the investigational drug, BT7480, will be a safe and effective anticancer therapy. This is the first time BT7480 will be given to humans. BT7480 is designed to recognize and attach itself to both the Nectin-4 protein found on the surface of some cancer cells and CD137, a protein found on the surface of some immune cells. BT7480 binds to both Nectin-4 and CD137 and may activate immune cells to fight the Nectin-4- expressing cancers.
Are you Eligible? (Inclusion Criteria)
- Must be aged 18 years or older.
- Must have locally advanced or metastatic disease that cannot be treated with standard therapy.
- Must have a confirmed diagnosis of malignant solid tumor associated with Nectin-4 expression, including urothelial (transitional cell) carcinoma; head and neck squamous cell carcinoma; non-small cell lung cancer; and ovarian, breast, gastric, or esophageal carcinoma.
Specialty Area(s)
Bladder Cancer , Breast Cancer, Esophageal Cancer, Ovarian Cancer, Head and Neck/Oral Cancers, Lung cancer, Stomach Cancer, Immunotherapy
Principal Investigator
Trial Location(s)
CUIMC/Herbert Irving Pavilion
161 Fort Washington Avenue
New York, NY 10032
